Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Santiago Compostela
Clinical trial register · Spain

Clinical Trials in Santiago Compostela, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 111 Madrid 100 Valencia 42 Santiago Compostela 30 Seville 30
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Novartis Pharmaceuticals30 Janssen Research & Development, LLC1 Bristol-Myers Squibb1 Clear sponsor filter
Site location
Barcelona111 Madrid100 Valencia42 Santiago Compostela30 Seville30
All 75 locations
Target enrolment
to

Trials with a site in Santiago Compostela

30 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Recruiting
Novartis Pharmaceuticals
Phase 3
188
Santiago Compostela, Sabadell, Seville
2026-08-04
Recruiting
Novartis Pharmaceuticals
Phase 3
5,700
Santiago Compostela, Seville, Badalona, L'Hospitalet de Llobregat, Santander, Cáceres, Reus, A Coruña
2026-05-11
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Santiago Compostela, Sant Cugat Del V, Burjassot, Córdoba
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 1/2
188
Santiago Compostela, L'Hospitalet de Llobregat, Madrid
2025-10-15
Recruiting
Novartis Pharmaceuticals
Phase 3
300
Santiago Compostela, Huelva, El Palmar, Las Palmas GC, Madrid, Salamanca, Seville, Valencia
2025-10-03
Active, closed
Novartis Pharmaceuticals
Phase 1
57
Santiago Compostela, Barcelona
2025-06-12
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Santiago Compostela, Pamplona, Castilleja de la Cuesta, A Coruña, Barcelona, Córdoba, Huelva, Las Palmas GC
2025-04-30
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca
2024-12-17
Recruiting
Novartis Pharmaceuticals
Phase 1
106
Santiago Compostela, Majadahonda, Barcelona
2024-11-11
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca
2024-10-29
Recruiting
Novartis Pharmaceuticals
Phase 1/2
232
Santiago Compostela, Marbella, Toledo, Barcelona, Las Palmas de Gran C, Seville
2024-10-24
Active, closed
Novartis Pharmaceuticals
Phase 2
251
Santiago Compostela, L'Hospitalet de Llobregat, Barcelona, Valencia
2024-10-17
Active, closed
Novartis Pharmaceuticals
Phase 1
54
Santiago Compostela, Barcelona, Madrid
2024-10-08
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Salamanca, Valencia
2024-09-04
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Santiago Compostela, L'Hospitalet de Llobregat, Alicante, Barcelona, Lleida, Madrid, Málaga, Valencia
2024-07-31
Active, closed
Novartis Pharmaceuticals
Phase 2
155
Santiago Compostela, A Coruña, Madrid
2024-07-02
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Santiago Compostela, Badalona, Santander, Barcelona, San Sebastian Reyes, Madrid, Valencia
2024-05-21
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Santiago Compostela, Barcelona, Córdoba, Málaga, Seville, Valencia
2024-02-28
Active, closed
Novartis Pharmaceuticals
Phase 3
109
Santiago Compostela, L'Hospitalet de Llobregat, Santander, El Palmar, Barcelona, Córdoba, Madrid, Salamanca
2023-10-02
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Ferrol, Santiago, Santiago Compostela, Elche, Granada, Huelva, Marbella, Málaga
2023-03-09
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Santiago Compostela, Elche, Badalona, Santander, Barcelona, San Sebastian Reyes, Pamplona, Vigo
2023-03-02
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Santiago Compostela, Salamanca
2023-02-02
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
Santiago Compostela, Badalona, L'Hospitalet de Llobregat, Bilbao, Santa Cruz, Barcelona, Madrid, Seville
2022-08-30
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Santiago Compostela, Pamplona, Vigo, San Cristóbal de La Laguna, Valencia, Barcelona, Madrid
2022-07-14
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Santiago Compostela, Vitoria-Gasteiz, L'Hospitalet de Llobregat, Albacete, Barcelona, Logroño, Pozuelo de Alarcón, Torrejón de Ardoz
2021-12-13
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Ferrol, Santiago Compostela, Seville, Mallorca, Palma, el Prat de Llobregat, L'Hospitalet de Llobregat, Sabadell
2021-11-23
Active, closed
Novartis Pharmaceuticals
Phase 3
208
Santiago Compostela, Donostia / San Sebastian, Barcelona
2021-07-27
Active, closed
Novartis Pharmaceuticals
Phase 3
469
Santiago Compostela, L'Hospitalet de Llobregat, El Palmar, Pamplona, Valencia, Barcelona, Madrid, Málaga
2021-06-15
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
DrugsTNO155·Opnurasib·Tislelizumab
Novartis Pharmaceuticals
Phase 1/2
344
Santiago Compostela, L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia
2021-02-24
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Santiago Compostela, Málaga, L'Hospitalet de Llobregat, Bilbao, Santander, Vigo, A Coruña, Madrid
2020-12-22
Rows per page Showing 1–30 of 30
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/santiago-compostela

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 30 of those studies with a site in Santiago Compostela that also match the filters currently applied.

How many clinical trials are recruiting in Santiago Compostela?

11 of the 30 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 19 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Santiago Compostela), 30 studies
PhaseStudiesRecruitingShare
Phase 316553.3%
Phase 26120%
Phase 13110%
Phase 1/23210%
Phase 4226.7%

Most active sponsors

Lead sponsors with the most studies (Santiago Compostela)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals3011
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.